MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
28 mai 2019 08h30 HE
|
MyoKardia, Inc.
First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable...